Title: Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.
Journal: Chemical research in toxicology20150518
Title: Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells.
Journal: International journal of oncology20140701
Title: KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in non-small cell lung cancer cells.
Journal: Molecular cancer therapeutics20140601
Title: Pemetrexed downregulates ERCC1 expression and enhances cytotoxicity effected by resveratrol in human nonsmall cell lung cancer cells.
Journal: Naunyn-Schmiedeberg's archives of pharmacology20131201
Title: Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC).
Journal: Cancer treatment reviews20130501
Title: Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology20130101
Title: Pemetrexed alters folate phenotype and inflammatory profile in EA.hy 926 cells grown under low-folate conditions.
Journal: European journal of pharmacology20121205
Title: Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line.
Journal: Current oncology (Toronto, Ont.)20120601
Title: Death receptor 5 and cellular FLICE-inhibitory protein regulate pemetrexed-induced apoptosis in human lung cancer cells.
Journal: European journal of cancer (Oxford, England : 1990)20111101
Title: Establishment of pemetrexed-resistant non-small cell lung cancer cell lines.
Journal: Cancer letters20111028
Title: Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-glycinamide ribonucleotide formyltransferase.
Journal: Journal of medicinal chemistry20111027
Title: Medical treatment of mesothelioma: anything new?
Journal: Current oncology reports20110801
Title: Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines.
Journal: Lung cancer (Amsterdam, Netherlands)20110701
Title: Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer20110501
Title: Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer20110401
Title: Targeted therapies and other agents as first-line maintenance and beyond: particular benefit in pulmonary adenocarcinoma patients.
Journal: Current medicinal chemistry20110101
Title: ABCC11/MRP8 confers pemetrexed resistance in lung cancer.
Journal: Cancer science20101101
Title: Pemetrexed in advanced non-small-cell lung cancer.
Journal: Expert opinion on pharmacotherapy20100601
Title: Cancer chemotherapy: targeting folic acid synthesis.
Journal: Cancer management and research20100101
Title: Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology20091001
Title: Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology20090710
Title: Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20090415
Title: A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20070615
Title: Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels.
Journal: British journal of cancer20070312
Title: Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow.
Journal: Anticancer research20070101
Title: [Pemetrexed: from preclinic to clinic].
Journal: Bulletin du cancer20070101
Title: A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy.
Journal: Cancer chemotherapy and pharmacology20060401
Title: Pemetrexed-associated urticarial vasculitis.
Journal: Lung cancer (Amsterdam, Netherlands)20060201
Title: The inverse relationship between reduced folate carrier function and pemetrexed activity in a human colon cancer cell line.
Journal: Molecular cancer therapeutics20060201
Title: Pemetrexed: a multitargeted antifolate.
Journal: Clinical therapeutics20050901
Title: Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators.
Journal: Cancer research20050801
Title: Cytotoxic effects of pemetrexed in gastric cancer cells.
Journal: Cancer science20050601
Title: The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites.
Journal: Molecular cancer therapeutics20050501
Title: The roles of thymidylate synthase and p53 in regulating Fas-mediated apoptosis in response to antimetabolites.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20040515
Title: Accumulation of 5-phosphoribosyl-1-pyrophosphate in human CCRF-CEM leukaemia cells treated with antifolates.
Journal: The international journal of biochemistry & cell biology20040301
Title: Thymidine rescue: an antidote for pemetrexed-related toxicity in the setting of acute renal failure.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology20031101
Title: Pemetrexed (Alimta): a novel multitargeted antifolate agent.
Journal: Expert review of anticancer therapy20030401
Title: Design, synthesis, and biological activities of classical N-[4-[2-(2-amino-4-ethylpyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and its 6-methyl derivative as potential dual inhibitors of thymidylate synthase and dihydrofolate reductase and as potential antitumor agents.
Journal: Journal of medicinal chemistry20030213
Title: Pemetrexed combination therapy in the treatment of non-small cell lung cancer.
Journal: Seminars in oncology20020401
Title: A new route to 7-substituted derivatives of n-[4-(2-[2-amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimidin-5-yl]ethyl)benzoyl]-L-glutamic acid [ALIMTA (LY231514, MTA)].
Journal: The Journal of organic chemistry20010601
Title: Shih C, et al. LY231514, a pyrrolo,3-dpyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997 Mar 15;57(6):1116-23.
Title: Anraku M, et al. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignantmesothelioma. J Immunol. 2010 Jul 15;185(2):956-66.
